Dapagliflozin Gets Breakthrough Therapy Status for CKD Indication
The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.
Diabetic Nephropathy
Updated ADA Guideline Recommends Combo Tx for Type 2 Diabetes With CKD
The 2020 ADA guideline update reflects evidence from recent major trials with cardiovascular and renal outcomes.
Dapagliflozin Reduces Kidney Failure Risk, Prolongs Survival in CKD
Dapagliflozin appears to preserve kidney function and improve survival in patients with chronic kidney disease whether or not they have type 2 diabetes.
Empagliflozin Beneficial in Heart Failure With Reduced Ejection Fraction
In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction.
Boxed Warning Removed From Canagliflozin Labeling
The FDA concluded “the risk no longer meets the standard for a Boxed Warning.”
Trial Investigating Dapagliflozin in CKD Meets All End Points
The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
Long-Term Risk for Severe Kidney Disease High in Those With T2DM
Onset at younger age with longer diabetes duration may add to risk for end-stage kidney disease.
High Prevalence of Americans Have Conditions Linked to Severe COVID-19
Median prevalence of any underlying medical condition is 47.2% for residents in all 50 states, DC.
Increased Renal ACE2 in Diabetic Nephropathy May Up COVID-19 Kidney Infection Risk
SARS-CoV-2, the virus that causes COVID-19, enters cells by binding to ACE2 on cell surfaces. Investigators performed a comparative analysis of specimens of diabetic kidney disease tissue and healthy tissue for ACE2 expression.
Finerenone Found to Delay Progression of Diabetic Kidney Disease
Early results from the phase 3 FIDELIO-DKD study also show that finerenone reduces the risk for a cardiovascular secondary endpoint in patients with diabetic kidney disease.
-
Loading...
-
Loading...
Next post in Diabetic Nephropathy
